Graves Ophthalmopathy Clinical Trial
Official title:
Comparative Morphometric, Functional and Psychosocial Analysis Between the Results of Two Surgical Techniques of Orbital Decompression in Patients With Graves Orbitopathy
Verified date | August 2019 |
Source | University of Sao Paulo General Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Randomized prospective clinical trial, aiming to compare two techniques of orbital decompression. Patients with Graves orbitopathy in the inactive phase for at least 6 months will be divided in two groups; one group will be submitted to orbital decompression by antro-ethmoidal technique; the other group will be submitted to orbital decompression by lateral wall technique. Patients will be followed up for a period of 6 months after the surgery, and will be evaluated about the effect of orbital decompression on ocular motility, proptosis, ocular surface and quality of life.
Status | Completed |
Enrollment | 42 |
Est. completion date | January 31, 2019 |
Est. primary completion date | January 31, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years and older |
Eligibility |
Inclusion Criteria: - Diagnosis of Graves orbitopathy for at least 2 years - Clinical Activity Score (CAS) < 4 for at least 6 months - Agreement with the Informed Consent Form, which will be signed during the selection visit - Ability to come to periodic evaluations for 6 months after the orbital decompression - Absence of ocular abnormalities such as degenerative myopia, microphthalmia or anophthalmic cavity - Absence of orbital abnormalities such as previous fractures or congenital defects - Good collaboration for the exams - Euthyroidism - Exophthalmus = 20 mm in Hertel's exophthalmometry - Preoperative clinical evaluation indicating absence of contraindications for a surgical procedure Exclusion Criteria: - Myasthenia gravis - Pregnancy - Previous orbital, strabismus or eyelid surgery - Other abnormal eye conditions or symptoms that make it impossible to admit the patient to the study, according to the clinical judgment of the investigator. |
Country | Name | City | State |
---|---|---|---|
Brazil | University of Sao Paulo General Hospital | São Paulo |
Lead Sponsor | Collaborator |
---|---|
University of Sao Paulo General Hospital |
Brazil,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Ocular Motility status | Measure by prism and cover, to assess strabismus in the nine positions of gaze | Before orbital decompression and 1, 3 and 6 months after surgery | |
Primary | Exophthalmos | Exophthalmos will be measured by Hertel's exophthalmometer and orbital computerized tomography | Before orbital decompression and 6 months after surgery | |
Secondary | Diplopia | Evaluation by Gorman's Diplopia Table | Before orbital decompression and 1, 3 and 6 months after surgery | |
Secondary | Digital photography evaluation | Using digital photography, Photoshop and Image J, ductions and versions will be analyzed | Before orbital decompression and 6 months after surgery | |
Secondary | Volume of the extraocular muscles | Measure by orbital computerized tomography images | Before orbital decompression and 6 months after surgery | |
Secondary | Ocular surface evaluation | Assessed by Lysozyme Green, Break-up time, Schirmer I test | Before orbital decompression and 6 months after surgery | |
Secondary | Quality of life questionary Quality of life questionary | GO-QoL form | Before orbital decompression and 6 months after surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05532072 -
Rapamycin Plus Methylprednisolone Versus Methylprednisolone Alone in Active, Moderate-to-severe Graves' Orbitopathy.
|
Early Phase 1 | |
Completed |
NCT01727973 -
Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy
|
Phase 1/Phase 2 | |
Recruiting |
NCT06112340 -
A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
|
Phase 2/Phase 3 | |
Recruiting |
NCT05678374 -
Exploring Immunological Markers Associated With Mental Fatigue in Graves' Disease
|
||
Recruiting |
NCT03708627 -
Bimatoprost as a Treatment for Graves' Orbitopathy
|
Early Phase 1 | |
Not yet recruiting |
NCT06413043 -
Study on Efficacy of Add on Selenium in Mild-to-moderate Graves Ophthalmopathy
|
N/A | |
Withdrawn |
NCT01379196 -
Use of Azithromycin as Immunomodulatory Therapy in Grave&Apos;s Orbitopathy
|
Phase 1/Phase 2 | |
Recruiting |
NCT06275373 -
The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
|
||
Recruiting |
NCT06226545 -
A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease
|
Phase 2 | |
Recruiting |
NCT05126147 -
Hydroxychloroquine in Mild Graves' Orbitopathy
|
Phase 4 | |
Recruiting |
NCT01999790 -
Comparison Study Between Two Techniques for Correction of Upper Lid Retraction in Patients With Grave's Orbitopathy
|
N/A | |
Recruiting |
NCT03066076 -
Total Thyroidectomy Versus Thionamides in Patients With Moderate-to-Severe Graves' Ophthalmopathy
|
Phase 3 | |
Active, not recruiting |
NCT03122847 -
Glucocorticoids and Bone in Graves' Ophthalmopathy
|
||
Terminated |
NCT01893450 -
Bromocriptine and Pentoxifylline in Ophthalmopathy Autoimmune Treatment
|
N/A | |
Completed |
NCT00348413 -
Thyroid Treatment Trial
|
N/A | |
Completed |
NCT03498417 -
Anti-insulin-like Growth Factor-1 Receptor (IGF-1R) Antibodies in Graves' Disease and Graves' Orbitopathy
|
||
Not yet recruiting |
NCT04598815 -
Sirolimus for Graves' Orbitopathy (GO)
|
Phase 2 | |
Terminated |
NCT01114503 -
A Safety and Tolerability Study of Otelixizumab in Thyroid Eye Disease
|
Phase 2 | |
Completed |
NCT05775185 -
Therapeutic Efficacy of Orbital Radiotherapy in Patients With Graves' Orbitopathy
|
||
Completed |
NCT05793359 -
Comparison of the Effectiveness of Two Glucocorticoid Regimens for Treatment of Graves' Orbitopathy
|